# TLN-121

Source: https://onco.cc/drugs/tln-121/  
OnCo record `tln-121` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TLN-121 is an experimental protein degrader from Treeline Biosciences, in phase 1 trials for B-cell lymphoma, T-cell lymphoma and non-Hodgkin lymphoma.

## Summary

TLN-121 is a protein degrader (small molecule) from Treeline Biosciences. Designed to remove the protein BCL6, which some lymphoma cells use to switch off genes, while avoiding off-target effects. Its furthest stage is phase 1, for B-cell lymphoma, T-cell lymphoma and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Registry NCT07082803 phase 1 recruiting, alone and with zeprumetostat (TLN-254). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: TLN-121
- Modality: Protein degrader (small molecule)
- Mechanism: Designed to remove the protein BCL6, which some lymphoma cells use to switch off genes, while avoiding off-target effects.

## Sources

- Treeline Biosciences: treeline.bio: https://treeline.bio/medicines
- Treeline Biosciences: treeline.bio: https://treeline.bio/medicines
- ClinicalTrials.gov: trials of TLN-121: https://clinicaltrials.gov/search?intr=TLN-121

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [BCL6](https://onco.cc/targets/bcl6/)
- companies: [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/)
- trials: [TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas](https://onco.cc/trials/nct07082803/)

---
JSON: https://onco.cc/api/v1/entities/tln-121.json